| Literature DB >> 28511220 |
Claudia Gasch1, Stefan Körber2, Christophe Kremer3, Matthias Eiber4, Clemens Kratochwil3, Uwe Haberkorn3, Markus Hohenfellner1, Boris Hadaschik1, Frederik L Giesel3.
Abstract
In recent years, PSMA-targeting PET tracers such as 68Ga-PSMA-11 have shown promising results, thus contributing to a better management of prostate cancer patients. At the present time, 68Ga-PSMA-11 is most frequently used for diagnostic evaluation in the setting of biochemical recurrence of prostate cancer. In this context, the 68Ga-PSMA-11 PET/CT delivers superior detection rates compared to conventional imaging, especially for the detection of small, unsuspicious lesions or lesions in the presence of low PSA values. Furthermore, 68Ga-PSMA PET imaging seems to be an encouraging alternative for the staging of high-risk patients, particularly in combination with multiparametric MRI. In addition to the increasing use of PSMA ligands in clinical diagnostics, some variants have also been successfully applied in therapy. Advanced metastasized prostate cancer patients showed a good response to PSMA radioligand therapy with tolerable side-effects after failure of guideline-compliant treatment.Due to recent developments, PSMA ligands will continue to play an important role in the management of prostate cancer patients and will be more widely used in the future. © Georg Thieme Verlag KG Stuttgart · New York.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28511220 DOI: 10.1055/s-0043-100269
Source DB: PubMed Journal: Aktuelle Urol ISSN: 0001-7868 Impact factor: 0.658